A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Cherry Thomas, MD
Wugen, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- Hospital Saint- Louis
Paris, France
- University Hospital Robert Debre
Paris, France
- Erasmus Mc
Rotterdam, Netherlands
- Prinses Maxima Centrum
Utrecht, Netherlands
- City of Hope
Duarte, California, United States
- Children'S Hospital Los Angeles
Los Angeles, California, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Washington University
St Louis, Missouri, United States
- Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- Vanderbilt University
Nashville, Tennessee, United States
- University of Wisconsin
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Jan 2022
- Primary completion
- 8 Aug 2024
- Completion
- 8 Aug 2024
- Last update posted
- 30 Sept 2025
- Registered enrollment
- 28
- Registry id
- NCT04984356
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.